Payment overview · 2025
General Payments
$705.84
38 reported records · 15 companies
Healthcare provider profile · identity verified
Beena Syed
Allopathic & Osteopathic Physicians|Internal Medicine · FORT SMITH, AR · NPI 1275840480
Verified facts
What the public records show
CMS Open Payments records show Beena Syed received $705.84 in general payments during 2025 across 38 reported records.
AstraZeneca Pharmaceuticals LP accounted for 31.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 170 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $222.86 | 31.6% | 9 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $81.52 | 11.6% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $72.42 | 10.3% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $57.42 | 8.1% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $46.62 | 6.6% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $41.88 | 5.9% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $33.03 | 4.7% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $22.11 | 3.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.59 | 3.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.05 | 2.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $18.91 | 2.7% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $17.68 | 2.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.96 | 2.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.44 | 2.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.35 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $705.84 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $173.58 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $120.93 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $99.85 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $81.52 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $54.20 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $42.73 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $42.73 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $42.73 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $36.33 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $33.03 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $32.51 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $32.51 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $28.33 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $28.28 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $22.11 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.59 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.05 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16.44 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.69 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.69 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.11 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 61 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 105 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 178 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
59 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
61 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
178 | 32 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
105 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
170 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 880 | 213 |
| Levothyroxine Sodium | Levothyroxine Sodium | 813 | 150 |
| Amlodipine Besylate | Amlodipine Besylate | 737 | 171 |
| Gabapentin | Gabapentin | 475 | 101 |
| Losartan Potassium | Losartan Potassium | 461 | 108 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 435 | 92 |
| Pantoprazole Sodium | Pantoprazole Sodium | 433 | 104 |
| Sertraline Hcl | Sertraline Hcl | 370 | 91 |
| Lisinopril | Lisinopril | 359 | 96 |
| Omeprazole | Omeprazole | 359 | 90 |
| Furosemide | Furosemide | 344 | 78 |
| Hydrochlorothiazide | Hydrochlorothiazide | 321 | 89 |
| Trazodone Hcl | Trazodone Hcl | 299 | 73 |
| Tramadol Hcl | Tramadol Hcl | 296 | 70 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 287 | 87 |
| Metformin Hcl Er | Metformin Hcl | 263 | 64 |
| Metoprolol Tartrate | Metoprolol Tartrate | 260 | 66 |
| Duloxetine Hcl | Duloxetine Hcl | 253 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 231 | 48 |
| Metformin Hcl | Metformin Hcl | 216 | 59 |
| Meloxicam | Meloxicam | 213 | 54 |
| Potassium Chloride | Potassium Chloride | 213 | 58 |
| Glipizide | Glipizide | 198 | 48 |
| Clonazepam | Clonazepam | 195 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 189 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 188 | 38 |
| Pregabalin | Pregabalin | 187 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 179 | 59 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 178 | 32 |
| Eliquis | Apixaban | 170 | 32 |
| Carvedilol | Carvedilol | 169 | 39 |
| Montelukast Sodium | Montelukast Sodium | 145 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 141 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 137 | 40 |
| Tizanidine Hcl | Tizanidine Hcl | 134 | 30 |
| Allopurinol | Allopurinol | 126 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 126 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 125 | 36 |
| Valsartan | Valsartan | 119 | 32 |
| Ezetimibe | Ezetimibe | 118 | 15 |
| Atenolol | Atenolol | 110 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 108 | 25 |
| Memantine Hcl | Memantine Hcl | 106 | 18 |
| Ozempic | Semaglutide | 105 | 33 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 103 | 20 |
| Alendronate Sodium | Alendronate Sodium | 102 | 29 |
| Buspirone Hcl | Buspirone Hcl | 99 | 23 |
| Diazepam | Diazepam | 97 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 95 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 95 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 94 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 93 | 26 |
| Myrbetriq | Mirabegron | 82 | 11 |
| Xarelto | Rivaroxaban | 82 | 12 |
| Simvastatin | Simvastatin | 81 | 17 |
| Alprazolam | Alprazolam | 78 | 20 |
| Lovastatin | Lovastatin | 78 | 20 |
| Prednisone | Prednisone | 76 | 40 |
| Propranolol Hcl | Propranolol Hcl | 76 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 76 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 76 | 19 |
| Estradiol | Estradiol | 72 | 21 |
| Finasteride | Finasteride | 71 | 17 |
| Nystatin | Nystatin | 70 | 31 |
| Warfarin Sodium | Warfarin Sodium | 70 | suppressed |
| Temazepam | Temazepam | 67 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 64 | 14 |
| Clonidine Hcl | Clonidine Hcl | 63 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 63 | 17 |
| Jardiance | Empagliflozin | 61 | 16 |
| Synthroid | Levothyroxine Sodium | 59 | 13 |
| Mirtazapine | Mirtazapine | 57 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 57 | 46 |
| Ondansetron Odt | Ondansetron | 57 | 22 |
| Famotidine | Famotidine | 56 | 20 |
| Donepezil Hcl | Donepezil Hcl | 55 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 54 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 53 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 53 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 52 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 52 | 11 |
| Glipizide Er | Glipizide | 49 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 47 | 40 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 47 | suppressed |
| Bupropion Xl | Bupropion Hcl | 46 | suppressed |
| Aripiprazole | Aripiprazole | 45 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 43 | suppressed |
| Eszopiclone | Eszopiclone | 41 | 13 |
| Nitroglycerin | Nitroglycerin | 41 | 24 |
| Lansoprazole | Lansoprazole | 40 | suppressed |
| Nifedipine Er | Nifedipine | 40 | 11 |
| Bupropion Hcl | Bupropion Hcl | 39 | suppressed |
| Sucralfate | Sucralfate | 38 | 13 |
| Baclofen | Baclofen | 37 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | suppressed |
| Cephalexin | Cephalexin | 37 | 26 |
| Lorazepam | Lorazepam | 37 | 12 |
| Amoxicillin | Amoxicillin | 36 | 33 |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Primidone | Primidone | 36 | suppressed |
| Risperidone | Risperidone | 36 | suppressed |
| Trulicity | Dulaglutide | 36 | suppressed |
| Fluconazole | Fluconazole | 35 | 23 |
| Entresto | Sacubitril/Valsartan | 34 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 32 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 30 | suppressed |
| Calcitriol | Calcitriol | 30 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 29 | suppressed |
| Celecoxib | Celecoxib | 28 | suppressed |
| Ibuprofen | Ibuprofen | 28 | 25 |
| Spironolactone | Spironolactone | 28 | suppressed |
| Methocarbamol | Methocarbamol | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 20 |
| Topiramate | Topiramate | 27 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Methotrexate | Methotrexate Sodium | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 22 | 20 |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 18 |
| Methylprednisolone | Methylprednisolone | 21 | 20 |
| Oxcarbazepine | Oxcarbazepine | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 17 |
| Benztropine Mesylate | Benztropine Mesylate | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Sulfasalazine | Sulfasalazine | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Zonisamide | Zonisamide | 15 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 14 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Dipyridamole | Dipyridamole | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Orencia Clickject | Abatacept | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Admelog Solostar | Insulin Lispro | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Constulose | Lactulose | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Timolol Maleate | Timolol Maleate/Pf | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $705.84 · 38 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, COMIRNATY, Dexcom G6 Transmitter, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, Kerendia, LEQVIO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, REPATHA, Rybelsus, SHINGRIX, Symbravo, TRELEGY ELLIPTA, TZIELD, UBRELVY, XIFAXAN, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error